LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: CRITICAL REVIEW OF AVAILABLE TREATMENT OPTIONS FOR TREATMENT REFRACTORY DEPRESSION AND ANXIETY - CLINICAL AND ETHICAL DILEMMAS.

    Kolar, Dusan / Kolar, Michael V

    Medicinski pregled

    2018  Volume 69, Issue 5-6, Page(s) 171–176

    Abstract: Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting ...

    Abstract Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Beozodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating maior depressive disorder but without sustained benefits. Loog-term use may pose a signiticant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds mor as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions. but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropriateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.
    MeSH term(s) Anxiety Disorders/therapy ; Depressive Disorder, Treatment-Resistant/therapy ; Ethics ; Humans
    Language English
    Publishing date 2018-04-25
    Publishing country Serbia
    Document type Journal Article ; Review
    ZDB-ID 131108-6
    ISSN 0025-8105
    ISSN 0025-8105
    DOI 10.2298/mpns1606171k
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Critical review of available treatment options for treatment refractory depression and anxiety - clinical and ethical dilemmas

    Kolar Dušan / Kolar Michael V.

    Medicinski Pregled, Vol 69, Iss 5-6, Pp 171-

    2016  Volume 176

    Abstract: Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting ...

    Abstract Treatment-resistant mood and anxiety disorders require an intensive therapeutic approach, and it should balance benefits and adverse effects or other potential detrimental effects of medications. The goal of treatment is to provide consistent and lasting improvement in symptoms of depression and anxiety. Benzodiazepines are effective for anxiety symptoms, but with no sustained treatment effects. Other medication treatment options for anxiety disorders are outlined. Ketamine is usually very effective in treating major depressive disorder but without sustained benefits. Long-term use may pose a significant risk of developing tolerance and dependence. Stimulant medication augmentation for treatment-resistant depression is effective for residual symptoms of depression, but effects are usually short-lasting and it sounds more as an artificial way of improving energy, alertness and cognitive functioning. Synthetic cannabinoids and medical marijuana are increasingly prescribed for various medical conditions, but more recently also for patients with mood and anxiety disorders. All of these treatments may raise ethical dilemmas about appropri­ateness of prescribing these medications and a number of questions regarding the optimal treatment for patients with treatment-resistant depression and treatment refractory anxiety disorders.
    Keywords Depressive Disorder ; Treatment-Resistant ; Anxiety Disorders ; Depression ; Treatment Outcome ; Risk Factors ; Benzo­diazepines ; Ketamine ; Pregabalin ; Central Nervous System Stimulants ; Cannabinoids ; Prescription Drug Overuse ; Drug-Related Side Effects and Adverse Reactions ; Medicine (General) ; R5-920 ; Medicine ; R
    Subject code 150
    Language Serbian
    Publishing date 2016-01-01T00:00:00Z
    Publisher Serbian Medical Society, Society of Physicians of Vojvodina, Novi Sad
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top